Literature DB >> 7947304

Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption.

E A Neuwelt1, P C Wiliams, B E Mickey, E P Frenkel, W D Henner.   

Abstract

In contrast to disseminated extraneural germinoma, systemic chemotherapy in disseminated central nervous system germinoma often results in only transient responses. After surgery, cytoreduction was accomplished with systemic multiagent platinum-based chemotherapy in 4 consecutive patients known to have a poor prognosis, due to central nervous system germinoma at more than one anatomic site. When tumor enhancement resolved (i.e., blood-brain barrier integrity was restored), intensive consolidation therapy with carboplatin and etoposide was given in association with mannitol-induced osmotic blood-brain barrier disruption. Complete responses occurred in all 4 patients and currently 3 are tumor-free without radiotherapy 24-40 months from diagnosis, suggesting the importance of increased drug delivery for an extended period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947304     DOI: 10.1159/000120809

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  3 in total

Review 1.  Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications.

Authors:  S I Rapoport
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

2.  Salvage radiation therapy for intracranial germinoma recurring after primary chemotherapy.

Authors:  Y Shibamoto; K Sasai; M Kokubo; M Hiraoka
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

Review 3.  Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

Authors:  David S Hersh; Aniket S Wadajkar; Nathan Roberts; Jimena G Perez; Nina P Connolly; Victor Frenkel; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.